Interferon-beta affects the tryptophan metabolism in multiple sclerosis patients
- PMID: 16053472
- DOI: 10.1111/j.1468-1331.2005.01041.x
Interferon-beta affects the tryptophan metabolism in multiple sclerosis patients
Abstract
Tryptophan and its metabolites are of great interest in understanding the pathogenesis of multiple sclerosis (MS). The total levels of tryptophan and its metabolites, kynurenine and kynurenic acid were determined in plasma by capillary liquid chromatography electrospray ionisation tandem mass spectrometry. This is the first report of the plasma levels of these analytes in healthy controls and relapsing-remitting MS patients receiving long-term and acute interferon-beta (IFN-beta) treatment. Twenty-four hours post-administration increased kynurenine levels (first IFN MS versus healthy, P = 0.042) and kynurenine/tryptophan ratio (K/T; first IFN MS versus healthy, P =0.027; first IFN MS versus long-term IFN MS, P = 0.036) were found. The long-term IFN MS group had higher K/T ratios at 4 and 12 h post-administration (P = 0.015 and 0.009, respectively). The increase of K/T ratio in the first IFN MS group indicate an induction of the enzyme indolamine-2,3-dioxygenase (IDO), as reported earlier in experimental allergic encephalomyelitis. As IDO is participating in both inflammatory and neurodegenerative processes, further knowledge of its involvement in the pathogenesis of MS is of great importance.
Similar articles
-
Dramatic changes in oxidative tryptophan metabolism along the kynurenine pathway in experimental cerebral and noncerebral malaria.Am J Pathol. 1998 Feb;152(2):611-9. Am J Pathol. 1998. PMID: 9466588 Free PMC article.
-
The norepinephrine level is decreased in the lymphocytes of long-term interferon-beta-treated multiple sclerosis patients.Mult Scler. 2006 Jun;12(3):265-70. doi: 10.1191/135248506ms1269oa. Mult Scler. 2006. PMID: 16764338
-
PRISMS: the story of a pivotal clinical trial series in multiple sclerosis.Curr Med Res Opin. 2010 Apr;26(4):827-38. doi: 10.1185/03007991003604018. Curr Med Res Opin. 2010. PMID: 20121658 Review.
-
Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.Clin Neuropharmacol. 2008 May-Jun;31(3):167-72. doi: 10.1097/wnf.0b013e3181571a8e. Clin Neuropharmacol. 2008. PMID: 18520983
-
[Selected issues of immunomodulating treatment in multiple sclerosis].Neurol Neurochir Pol. 2004 Jul-Aug;38(4):299-306. Neurol Neurochir Pol. 2004. PMID: 15383958 Review. Polish.
Cited by
-
The role of kynurenines in the pathomechanism of amyotrophic lateral sclerosis and multiple sclerosis: therapeutic implications.J Neural Transm (Vienna). 2012 Feb;119(2):225-34. doi: 10.1007/s00702-012-0765-3. Epub 2012 Jan 19. J Neural Transm (Vienna). 2012. PMID: 22258797 Review.
-
Kynurenines in the CNS: recent advances and new questions.Nat Rev Drug Discov. 2013 Jan;12(1):64-82. doi: 10.1038/nrd3793. Epub 2012 Dec 14. Nat Rev Drug Discov. 2013. PMID: 23237916 Review.
-
Impact of Exercise on Immunometabolism in Multiple Sclerosis.J Clin Med. 2020 Sep 21;9(9):3038. doi: 10.3390/jcm9093038. J Clin Med. 2020. PMID: 32967206 Free PMC article. Review.
-
Allosteric modulation of metabotropic glutamate receptor 4 activates IDO1-dependent, immunoregulatory signaling in dendritic cells.Neuropharmacology. 2016 Mar;102:59-71. doi: 10.1016/j.neuropharm.2015.10.036. Epub 2015 Oct 30. Neuropharmacology. 2016. PMID: 26522434 Free PMC article.
-
Kynurenines in the Pathogenesis of Multiple Sclerosis: Therapeutic Perspectives.Cells. 2020 Jun 26;9(6):1564. doi: 10.3390/cells9061564. Cells. 2020. PMID: 32604956 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials